1. |
Sapisochín G, Fernández de Sevilla E, Echeverri J, et al. Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol, 2015, 7(22): 2396-2403.
|
2. |
Yamamoto Y, Sugiura T, Todaka A, et al. Surgical indication for advanced intrahepatic cholangiocarcinoma according to the optimal preoperative carbohydrate antigen 19-9 cutoff value. World J Surg, 2018, 42(10): 3331-3340.
|
3. |
Cieslak KP, Huisman F, Bais T, et al. Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization. Surgery, 2017, 162(1): 37-47.
|
4. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019版). 中华消化外科杂志, 2020, 19(1): 1-20.
|
5. |
National Comprehensive Cancer Network (NCCN). ClinicalPractice Guidelines in Oncology. Hepatobiliary Cancers, Version 5.2020-08-04. https://www.nccn.org/professionals/ physician_gls/pdf/hepatobiliary.pdf.
|
6. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
7. |
Yeesoonsang S, McNeil E, Virani S, et al. Trends in incidence of two major subtypes of liver and bile duct cancer: hepatocellular carcinoma and cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030. J Cancer Epidemiol, 2018, 2018: 8267059. doi: 10.1155/2018/8267059.
|
8. |
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol, 2014, 60(6): 1268-1289.
|
9. |
Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol, 2014, 27(8): 1163-1173.
|
10. |
Zhang XF, Chakedis J, Bagante F, et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. Br J Surg, 2018, 105(7): 857-866.
|
11. |
Weber SM, Ribero D, O’Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford), 2015, 17(8): 691-699.
|
12. |
陈枫, 赵大伟, 文硕, 等. 肝内肿块型胆管癌的CT、MRI动态增强表现以及与病理分化程度的关系. 中华放射学杂志, 2015, 49(11): 843-847.
|
13. |
邸亮, 曾道炳. 精准医学时代肝内胆管细胞癌诊治进展. 中华肝脏外科手术学电子杂志, 2020, 9(1): 11-16.
|
14. |
Wang JK, Hu HJ, Shrestha A, et al. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget, 2017, 8(28): 45335-45344.
|
15. |
He C, Zhang Y, Song Y, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer, 2018, 9(17): 3117-3128.
|
16. |
Dolscheid-Pommerich RC, Manekeller S, Walgenbach-Brünagel G, et al. Clinical performance of CEA, CA19-9, CA15-3, CA125 and AFP in gastrointestinal cancer using LOCI™-based assays. Anticancer Res, 2017, 37(1): 353-359.
|
17. |
刘国. 利用超声鉴别诊断肝细胞肝癌、肝胆管细胞癌的临床价值. 影像研究与医学应用, 2018, 2(22): 150-151.
|
18. |
张梅, 丁洪彬. 螺旋CT和MRI诊断肝内胆管细胞癌的运用价值分析. 影像技术, 2019, 31(6): 39-42.
|
19. |
Zhao YJ, Chen WX, Wu DS, et al. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings. Abdom Radiol (NY), 2016, 41(5): 978-989.
|
20. |
陈佳妮. 肝内周围型胆管细胞癌的CT及MRI诊断价值对比评价. 影像研究与医学应用, 2018, 2(14): 174-175.
|
21. |
Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol, 2015, 16(3): 449-464.
|
22. |
Kim SY. Preoperative radiologic evaluation of cholangiocarcinoma. Korean J Gastroenterol, 2017, 69(3): 159-163.
|
23. |
Lee Y, Yoo IR, Boo SH, et al. The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging, 2017, 51(1): 69-78.
|
24. |
Ma KW, Cheung TT, She WH, et al. The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: A single-center experience. Medicine (Baltimore), 2016, 95(28): e4133. doi: 10.1097/MD.0000000000004133.
|
25. |
Tomimaru Y, Eguchi H, Wada H, et al. Liver resection combined with inferior vena cava resection and reconstruction using artificial vascular graft: A literature review. Ann Gastroenterol Surg, 2018, 2(3): 182-186.
|
26. |
中国医师协会肝癌专业委员会. 肝内胆管癌外科治疗中国专家共识(2020版). 中华消化外科杂志, 2021, 20(1): 1-15.
|
27. |
Hoyos S, Navas MC, Restrepo JC, et al. Current controversies in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1461-1467.
|
28. |
Brauer DG, Fields RC, Tan BR, et al. Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. HPB (Oxford), 2018, 20(5): 470-476.
|
29. |
Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg, 2018, 105(7): 839-847.
|
30. |
Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore), 2019, 98(5): e14013. doi: 10.1097/MD.0000000000014013.
|
31. |
王超群, 陆录, 钦伦秀. 肝内胆管细胞癌诊疗策略. 中华肝脏外科手术学电子杂志, 2020, 9(1): 1-5.
|
32. |
Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov, 2017, 7(3): 252-263.
|